Immune recovery following switch from EFV-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed immunological non-responders: a 144-week real-world cohort study in China - Report - MDSpire
Advertisement
Immune recovery following switch from EFV-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed immunological non-responders: a 144-week real-world cohort study in China
Clinical Report: Immune Recovery After Transitioning from EFV to BIC/FTC/TAF
Overview
Expand on the implications of the findings in relation to current treatment guidelines.
Background
Incorporate specific data or references regarding the prevalence of INRs in China.
Data Highlights
Adjust the table for clarity and include statistical significance where applicable.
Key Findings
The prevalence of INRs among PLWH on long-term ART in Chongqing, China, was found to be 29.9%.
Switching from EFV to BIC/FTC/TAF resulted in significantly greater increases in CD4 cell counts at weeks 48, 96, and 144.
Immune reconstitution rates were higher in the BIC/FTC/TAF group compared to the EFV group at both week 48 and week 144.
The immunological benefits of switching were primarily observed in patients aged ≤50 years.
Virological suppression rates remained high in both treatment groups throughout the study.
Clinical Implications
The findings suggest that switching from EFV-based regimens to BIC/FTC/TAF may enhance immune recovery in INRs, particularly in younger patients. Clinicians should consider this switch for eligible patients to potentially improve their immunological status while maintaining virological suppression.
Conclusion
The study highlights the potential benefits of switching ART regimens for immunological non-responders, emphasizing the need for further prospective studies to confirm these exploratory findings.
